Pharmaceutical firm Ipsen has completed the acquisition of ImCheck Therapeutics, a French private biotech specializing in novel immuno-oncology treatments. Founded in 2015, ImCheck is recognized for its advancements in next-generation therapies aimed at fighting cancer. This strategic purchase, valued at €1 billion, significantly expands Ipsen’s oncology portfolio and reinforces its commitment to innovation in cancer care.
Back
